| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Bascom Palmer Eye Institute, Department of Ophthalmology, The University of Miami School of Medicine, Miami, Florida; and the 2National Eye Institute, National Institutes of Health, Bethesda, Maryland.
PURPOSE. Macrophage recruitment to the choroid has been proposed to contribute to the pathogenesis of choroidal neovascularization (CNV) in AMD. The study was conducted to determine whether treatment with clodronate liposomes (CL2MDP-lip), which cause depletion of blood monocytes and lymph node macrophages, diminishes the severity of neovascularization in a mouse model of laser-induced CNV.
METHODS. Laser-induced CNV was performed in female 16-month-old C57BL/6 mice. Macrophages were depleted by use of CL2MDP-lip intraperitoneally and subcutaneously 72 and 24 hours before and every 2 to 3 days after laser injury. Control mice received injections of either PBS alone or PBS liposomes. Blood monocyte and choroidal macrophage depletion were documented by flow cytometry and choroidal flatmount preparation analysis, respectively. Two weeks after laser injury, mice were injected intravenously with fluoresceinated dextran. The right eyes were removed and prepared for flatmount analysis of CNV surface area (in relative disc areas or DA), vascularity (relative fluorescence), and cellularity (propidium iodide stain). The mice were then perfused with 10% formaldehyde, and the left eyes were removed for histopathology. The means of the various parameters for four CNV lesions per eye were calculated. Fluorescein angiography was also performed.
RESULTS. Flow cytometry of circulating monocytes and immunohistochemical analysis of choroidal macrophage density confirmed the effective depletion of blood monocytes and choroidal macrophages respectively in CL2MDP-lip–treated mice. Compared with the control, flatmount analysis of macrophage depleted mice demonstrated a significant reduction in size of the CNV area (2.8 ± 0.5 DA vs. 1.4 ± 0.1 DA; P < 0.043). The treated group also revealed less vascularity (1.6 ± 0.1 units vs. 1.1 ± 0.0 units; P < 0.0092) and cellularity of CNV lesions (3.3 ± 0.6 DA vs. 1.7 ± 0.1 DA, P < 0.04). Histopathology revealed that, in the macrophage-depleted group, CNV was smaller in diameter (1270 ± 73 pixels vs. 770 ± 82 pixels, P < 0.0006) and thickness (120 ± 7 pixels vs. 96 ± 7 pixels, P < 0.019).
CONCLUSIONS. Macrophage depletion using CL2MDP-lip reduces size, cellularity, and vascularity of CNV. This observation supports the hypothesis that macrophages contribute to the severity of CNV lesions.
This article has been cited by other articles:
|
|
 |
|
  M. H. Davies, A. J. Stempel, and M. R. Powers MCP-1 Deficiency Delays Regression of Pathologic Retinal Neovascularization in a Model of Ischemic Retinopathy Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 4195 - 4202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nakai, O. Fainaru, L. Bazinet, P. Pakneshan, O. Benny, E. Pravda, J. Folkman, and R. J. D'Amato Dendritic Cells Augment Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3666 - 3670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Noda, H. She, T. Nakazawa, T. Hisatomi, S. Nakao, L. Almulki, S. Zandi, S. Miyahara, Y. Ito, K. L. Thomas, et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization FASEB J, August 1, 2008; 22(8): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M-K Ezzat, C R Hann, S Vuk-Pavlovic, and J S Pulido Immune cells in the human choroid Br. J. Ophthalmol., July 1, 2008; 92(7): 976 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tatar, E. Yoeruek, P. Szurman, K. U. Bartz-Schmidt, A. Adam, K. Shinoda, C. Eckardt, V. Boeyden, C. Claes, G. Pertile, et al. Effect of Bevacizumab on Inflammation and Proliferation in Human Choroidal Neovascularization Arch Ophthalmol, June 1, 2008; 126(6): 782 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Izumi-Nagai, N. Nagai, K. Ohgami, S. Satofuka, Y. Ozawa, K. Tsubota, S. Ohno, Y. Oike, and S. Ishida Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1679 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lu, L. Li, K. Kuno, Y. Wu, T. Baba, Y.-y. Li, X. Zhang, and N. Mukaida Protective Roles of the Fractalkine/CX3CL1-CX3CR1 Interactions in Alkali-Induced Corneal Neovascularization through Enhanced Antiangiogenic Factor Expression J. Immunol., March 15, 2008; 180(6): 4283 - 4291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Qin, M. Ni, and G. W. De Vries Implication of S-Adenosylhomocysteine Hydrolase in Inhibition of TNF-{alpha}- and IL-1{beta}-Induced Expression of Inflammatory Mediators by AICAR in RPE Cells Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1274 - 1281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rao, I. B. Lobov, J. E. Vallance, K. Tsujikawa, I. Shiojima, S. Akunuru, K. Walsh, L. E. Benjamin, and R. A. Lang Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch Development, December 15, 2007; 134(24): 4449 - 4458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nagai, H. Imai, S. Honda, and A. Negi Antiangiogenic Effects of Bisphosphonates on Laser-Induced Choroidal Neovascularization in Mice Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5716 - 5721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Koto, N. Nagai, H. Mochimaru, T. Kurihara, K. Izumi-Nagai, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, et al. Eicosapentaenoic Acid Is Anti-Inflammatory in Preventing Choroidal Neovascularization in Mice Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4328 - 4334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Izumi-Nagai, N. Nagai, Y. Ozawa, M. Mihara, Y. Ohsugi, T. Kurihara, T. Koto, S. Satofuka, M. Inoue, K. Tsubota, et al. Interleukin-6 Receptor-Mediated Activation of Signal Transducer and Activator of Transcription-3 (STAT3) Promotes Choroidal Neovascularization Am. J. Pathol., June 1, 2007; 170(6): 2149 - 2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Giovannini, P. Neri, L. Mercanti, and C. Brue Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation Br. J. Ophthalmol., May 1, 2007; 91(5): 620 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kamei, K. Yoneda, N. Kume, M. Suzuki, H. Itabe, K.-i. Matsuda, T. Shimaoka, M. Minami, S. Yonehara, T. Kita, et al. Scavenger Receptors for Oxidized Lipoprotein in Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zamiri, S. Masli, J. W. Streilein, and A. W. Taylor Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3912 - 3918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Hageman, D. H. Anderson, L. V. Johnson, L. S. Hancox, A. J. Taiber, L. I. Hardisty, J. L. Hageman, H. A. Stockman, J. D. Borchardt, K. M. Gehrs, et al. From The Cover: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration PNAS, May 17, 2005; 102(20): 7227 - 7232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsuda, F. Gomi, Y. Oshima, M. Tohyama, and Y. Tano Vascular Endothelial Growth Factor Reduced and Connective Tissue Growth Factor Induced by Triamcinolone in ARPE19 Cells under Oxidative Stress Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1062 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Apte, R. A. Barreiro, E. Duh, O. Volpert, and T. A. Ferguson Stimulation of Neovascularization by the Anti-angiogenic Factor PEDF Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4491 - 4497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Tsutsumi-Miyahara, K-H Sonoda, K Egashira, M Ishibashi, H Qiao, T Oshima, T Murata, M Miyazaki, I F Charo, S Hamano, et al. The relative contributions of each subset of ocular infiltrated cells in experimental choroidal neovascularisation Br. J. Ophthalmol., September 1, 2004; 88(9): 1217 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Cousins, D. G. Espinosa-Heidmann, and K. G. Csaky Monocyte Activation in Patients With Age-Related Macular Degeneration: A Biomarker of Risk for Choroidal Neovascularization? Arch Ophthalmol, July 1, 2004; 122(7): 1013 - 1018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Espinosa-Heidmann, A. Caicedo, E. P. Hernandez, K. G. Csaky, and S. W. Cousins Bone Marrow-Derived Progenitor Cells Contribute to Experimental Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 4914 - 4919. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
